Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. more
Time Frame | TXG | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.79% | -3.39% | 0.2% |
1-Month Return | 11.76% | -1.92% | 2.72% |
3-Month Return | -31.2% | -10.54% | 7.31% |
6-Month Return | -26.28% | -4.47% | 10.44% |
1-Year Return | -72.69% | 4.06% | 27.53% |
3-Year Return | -89.73% | 0.94% | 30.88% |
5-Year Return | -76.25% | 36.67% | 89.21% |
10-Year Return | -72.08% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 245.89M | 298.85M | 490.49M | 516.41M | 618.73M | [{"date":"2019-12-31","value":39.74,"profit":true},{"date":"2020-12-31","value":48.3,"profit":true},{"date":"2021-12-31","value":79.27,"profit":true},{"date":"2022-12-31","value":83.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 61.03M | 58.47M | 74.09M | 120.39M | 209.41M | [{"date":"2019-12-31","value":29.14,"profit":true},{"date":"2020-12-31","value":27.92,"profit":true},{"date":"2021-12-31","value":35.38,"profit":true},{"date":"2022-12-31","value":57.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 184.86M | 240.38M | 416.40M | 396.02M | 409.31M | [{"date":"2019-12-31","value":44.39,"profit":true},{"date":"2020-12-31","value":57.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.11,"profit":true},{"date":"2023-12-31","value":98.3,"profit":true}] |
Gross Margin | 75.18% | 80.44% | 84.89% | 76.69% | 66.15% | [{"date":"2019-12-31","value":88.56,"profit":true},{"date":"2020-12-31","value":94.75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.33,"profit":true},{"date":"2023-12-31","value":77.93,"profit":true}] |
Operating Expenses | 213.93M | 325.70M | 469.31M | 563.97M | 674.95M | [{"date":"2019-12-31","value":31.7,"profit":true},{"date":"2020-12-31","value":48.26,"profit":true},{"date":"2021-12-31","value":69.53,"profit":true},{"date":"2022-12-31","value":83.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (29.07M) | (85.32M) | (52.91M) | (167.94M) | (265.33M) | [{"date":"2019-12-31","value":-2907100000,"profit":false},{"date":"2020-12-31","value":-8532400000,"profit":false},{"date":"2021-12-31","value":-5291300000,"profit":false},{"date":"2022-12-31","value":-16794400000,"profit":false},{"date":"2023-12-31","value":-26532900000,"profit":false}] |
Total Non-Operating Income/Expense | (2.24M) | (449.30M) | (1.46M) | 12.14M | 33.44M | [{"date":"2019-12-31","value":-6.69,"profit":false},{"date":"2020-12-31","value":-1343.65,"profit":false},{"date":"2021-12-31","value":-4.37,"profit":false},{"date":"2022-12-31","value":36.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (31.03M) | (534.48M) | (53.72M) | (161.97M) | (248.76M) | [{"date":"2019-12-31","value":-3103300000,"profit":false},{"date":"2020-12-31","value":-53447600000,"profit":false},{"date":"2021-12-31","value":-5371500000,"profit":false},{"date":"2022-12-31","value":-16197100000,"profit":false},{"date":"2023-12-31","value":-24876300000,"profit":false}] |
Income Taxes | 218.00K | 8.26M | 4.51M | 4.03M | 6.34M | [{"date":"2019-12-31","value":2.64,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":54.61,"profit":true},{"date":"2022-12-31","value":48.81,"profit":true},{"date":"2023-12-31","value":76.75,"profit":true}] |
Income After Taxes | (31.25M) | (542.73M) | (58.22M) | (166.00M) | (255.10M) | [{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}] |
Income From Continuous Operations | (31.25M) | (542.73M) | (58.22M) | (166.00M) | (255.10M) | [{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (31.25M) | (542.73M) | (58.22M) | (166.00M) | (255.10M) | [{"date":"2019-12-31","value":-3125100000,"profit":false},{"date":"2020-12-31","value":-54273100000,"profit":false},{"date":"2021-12-31","value":-5822300000,"profit":false},{"date":"2022-12-31","value":-16600000000,"profit":false},{"date":"2023-12-31","value":-25509900000,"profit":false}] |
EPS (Diluted) | (0.56) | (5.13) | (0.52) | (1.47) | (2.17) | [{"date":"2019-12-31","value":-56,"profit":false},{"date":"2020-12-31","value":-513,"profit":false},{"date":"2021-12-31","value":-52,"profit":false},{"date":"2022-12-31","value":-147,"profit":false},{"date":"2023-12-31","value":-217,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TXG | |
---|---|
Cash Ratio | 3.28 |
Current Ratio | 4.90 |
Quick Ratio | 4.12 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TXG | |
---|---|
ROA (LTM) | -11.37% |
ROE (LTM) | -24.87% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TXG | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.23 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.77 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TXG | |
---|---|
Trailing PE | NM |
Forward PE | 196.08 |
P/S (TTM) | 2.83 |
P/B | 2.51 |
Price/FCF | 100 |
EV/R | 2.39 |
EV/Ebitda | NM |
10X Genomics Inc (TXG) share price today is $13.333
Yes, Indians can buy shares of 10X Genomics Inc (TXG) on Vested. To buy 10X Genomics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TXG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of 10X Genomics Inc (TXG) via the Vested app. You can start investing in 10X Genomics Inc (TXG) with a minimum investment of $1.
You can invest in shares of 10X Genomics Inc (TXG) via Vested in three simple steps:
The 52-week high price of 10X Genomics Inc (TXG) is $57.78. The 52-week low price of 10X Genomics Inc (TXG) is $12.95.
The price-to-earnings (P/E) ratio of 10X Genomics Inc (TXG) is
The price-to-book (P/B) ratio of 10X Genomics Inc (TXG) is 2.51
The dividend yield of 10X Genomics Inc (TXG) is 0.00%
The market capitalization of 10X Genomics Inc (TXG) is $1.78B
The stock symbol (or ticker) of 10X Genomics Inc is TXG